These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21567417)

  • 21. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.
    Ujike M; Ejima M; Anraku A; Shimabukuro K; Obuchi M; Kishida N; Hong X; Takashita E; Fujisaki S; Yamashita K; Horikawa H; Kato Y; Oguchi A; Fujita N; Tashiro M; Odagiri T;
    Emerg Infect Dis; 2011 Mar; 17(3):470-9. PubMed ID: 21392439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.
    Butler J; Hooper KA; Petrie S; Lee R; Maurer-Stroh S; Reh L; Guarnaccia T; Baas C; Xue L; Vitesnik S; Leang SK; McVernon J; Kelso A; Barr IG; McCaw JM; Bloom JD; Hurt AC
    PLoS Pathog; 2014 Apr; 10(4):e1004065. PubMed ID: 24699865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011.
    Yang JR; Huang YP; Chang FY; Hsu LC; Huang HY; Pan YT; Lin YC; Wu HS; Liu MT
    J Med Virol; 2013 Mar; 85(3):379-87. PubMed ID: 23280715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
    Farrukee R; Gunalan V; Maurer-Stroh S; Reading PC; Hurt AC
    J Virol; 2022 Aug; 96(15):e0091822. PubMed ID: 35867563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.
    Ramirez-Gonzalez JE; Gonzalez-Duran E; Alcantara-Perez P; Wong-Arambula C; Olivera-Diaz H; Cortez-Ortiz I; Barrera-Badillo G; Nguyen H; Gubareva L; Lopez-Martinez I; Díaz-Quiñonez JA; Lezana-Fernández MA; Gatell-Ramírez HL; Cordova Villalobos JA; Hernández-Avila M; Alpuche-Aranda C
    Emerg Infect Dis; 2011 Feb; 17(2):283-6. PubMed ID: 21291607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.
    Deyde VM; Sheu TG; Trujillo AA; Okomo-Adhiambo M; Garten R; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1102-10. PubMed ID: 20028826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.
    Eshaghi A; Bolotin S; Burton L; Low DE; Mazzulli T; Drews SJ
    J Clin Virol; 2009 Jun; 45(2):142-5. PubMed ID: 19451021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
    Brookes DW; Miah S; Lackenby A; Hartgroves L; Barclay WS
    J Antimicrob Chemother; 2011 Mar; 66(3):466-70. PubMed ID: 21172786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China.
    Huang W; Li X; Cheng Y; Tan M; Guo J; Wei H; Zhao X; Lan Y; Xiao N; Wang Z; Wang D; Shu Y
    Virol J; 2015 Jun; 12():96. PubMed ID: 26103966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation.
    Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Iwakuni O; Egashira K; Yamaji K; Kashiwagi S
    J Infect Chemother; 2012 Apr; 18(2):180-6. PubMed ID: 22193710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
    Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
    J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance and oseltamivir resistance of human influenza a virus in Turkey during the 2007-2008 season.
    Ciblak MA; Hasoksuz M; Escuret V; Valette M; Gul F; Yilmaz H; Turan N; Bozkaya E; Badur S
    J Med Virol; 2009 Sep; 81(9):1645-51. PubMed ID: 19626608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
    Abed Y; Pizzorno A; Bouhy X; Boivin G
    Antiviral Res; 2015 Feb; 114():57-61. PubMed ID: 25512229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
    Kossyvakis A; Mentis AA; Tryfinopoulou K; Pogka V; Kalliaropoulos A; Antalis E; Lytras T; Meijer A; Tsiodras S; Karakitsos P; Mentis AF
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):361-371. PubMed ID: 27848039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of H275Y oseltamivir resistance gene mutation among Influenza A(H1N1)pdm09 patients by allelic discrimination real-time RT-PCR.
    Krishna S; Jayaram A; Shetty U; Varamballi P; Mukhopadhyay C; Jagadesh A
    J Med Virol; 2023 May; 95(5):e28764. PubMed ID: 37212286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
    Kim HM; Lee N; Kim MS; Kang C; Chung YS
    Virol J; 2020 Jul; 17(1):94. PubMed ID: 32631440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan.
    Yang JR; Huang YP; Lin YC; Su CH; Kuo CY; Hsu LC; Wu HS; Liu MT
    Antiviral Res; 2010 Dec; 88(3):256-62. PubMed ID: 20869989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
    Marjuki H; Mishin VP; Sleeman K; Okomo-Adhiambo M; Sheu TG; Guo L; Xu X; Gubareva LV
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5209-15. PubMed ID: 23917311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses.
    Carr MJ; Sayre N; Duffy M; Connell J; Hall WW
    J Virol Methods; 2008 Nov; 153(2):257-62. PubMed ID: 18718489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.